Human Multipotent Mesenchymal Stromal Cells in the Treatment of Postoperative Temporal Bone Defect: An Animal Model - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Cell Transplantation Année : 2016

Human Multipotent Mesenchymal Stromal Cells in the Treatment of Postoperative Temporal Bone Defect: An Animal Model

Résumé

Canal wall down mastoidectomy is one of the most effective treatments for cholesteatoma. However, it results in anatomical changes in the external and middle ear with a negative impact on the patient's quality of life. To provide complete closure of the mastoid cavity and normalize the anatomy of the middle and external ear, we used human multipotent mesenchymal stromal cells (hMSCs), GMP grade, in a guinea pig model. A method for preparing a biomaterial composed of hMSCs, hydroxyapatite, and tissue glue was developed. Animals from the treated group were implanted with biomaterial composed of hydroxyapatite and hMSCs, while animals in the control group received hydroxyapatite alone. When compared to controls, the group implanted with hMSCs showed a significantly higher ratio of new bone formation (p = 0.00174), as well as a significantly higher volume percentage of new immature bone (p = 0.00166). Our results proved a beneficial effect of hMSCs on temporal bone formation and provided a promising tool to improve the quality of life of patients after canal wall down mastoidectomy by hMSC implantation.
Fichier principal
Vignette du fichier
096368915x689730.pdf (753.41 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

hal-02000713 , version 1 (31-01-2019)

Identifiants

Citer

Lukas Skoloudik, Viktor Chrobok, David Kalfert, Zuzana Koci, Eva Sykova, et al.. Human Multipotent Mesenchymal Stromal Cells in the Treatment of Postoperative Temporal Bone Defect: An Animal Model. Cell Transplantation, 2016, 25 (7), pp.1405-1414. ⟨10.3727/096368915X689730⟩. ⟨hal-02000713⟩
56 Consultations
159 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More